Patents Assigned to ASTRAZENECA R&D
  • Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators
    Publication number: 20130203991
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 8, 2013
    Applicant: ASTRAZENECA R&D ALDERLY PARK
    Inventor: AstraZeneca R&D Alderly Park
  • CHEMICAL COMPOUNDS - 643
    Publication number: 20130203714
    Abstract: The invention concerns bicyclic compounds of Formula I wherein R1, R2, L1, L2, J, Y, k, n, p and r are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of androgen-receptor associated conditions, particularly prostate cancer.
    Type: Application
    Filed: August 1, 2012
    Publication date: August 8, 2013
    Applicant: ASTRAZENECA R&D
    Inventors: Robert Hugh Bradbury, Gregory Richard Carr, Alfred Arthur Rabow, Srinivasa Rao Korupoju, Harikrishna Tumma
  • SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL
    Publication number: 20110178064
    Abstract: In one aspect, the present invention relates to compounds of Formula (I): to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to method for their preparation.
    Type: Application
    Filed: July 16, 2008
    Publication date: July 21, 2011
    Applicant: ASTRAZENECA R&D
    Inventors: Gregory Steven Basarab, Jacques Dumas, Pamela Hill
  • DRY POWDER FORMULATIONS COMPRISING ASCORBIC ACID DERIVATES
    Publication number: 20110105449
    Abstract: The invention provides dry powder pharmaceutical formulations comprising an ascorbic acid derivative that demonstrate good inhalation performance and dry powder inhalers containing them.
    Type: Application
    Filed: November 6, 2008
    Publication date: May 5, 2011
    Applicant: ASTRAZENECA R&D
    Inventor: Jan Trofast
  • Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
    Publication number: 20100280048
    Abstract: The invention provides certain novel 6-heteroaryl-5-methyl-3-oxo-4-[3(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide derivatives and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: November 5, 2008
    Publication date: November 4, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Debra Ainge, David Chapman, Martin Lindsjo, Hans Lonn, Michael Lundkvist, Magnus Munck AF Rosen-Schold, Antonios Nikitidis, John Pavey
  • NOVEL COMBINATIONS
    Publication number: 20100261690
    Abstract: The invention provides a pharmaceutical product comprising, in combination, (1) a named glucocorticosteroid receptor agonist and (2) a ?2 adrenoreceptor agonist, a dual ?2 adrenoreceptor agonist/M3 receptor antagonist, a muscarinic antagonist, a p38 kinase inhibitor, a neutrophil elastase inhibitor, a phosphodiesterase PDE4 inhibitor, an IKK2 kinase inhibitor or a non-steroidal glucocorticoid receptor agonist, and the use of said product in treating respiratory diseases.
    Type: Application
    Filed: March 30, 2010
    Publication date: October 14, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Frank Burkamp, Peter Hansen
  • NOVEL AMIDE COMPOUNDS
    Publication number: 20100256104
    Abstract: The present invention provides compounds of formula (I) wherein n, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: March 30, 2010
    Publication date: October 7, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Frank Burkamp, Balint Gabos, Svetlana Ivanova, Alice Ingrid Annea Lisius
  • NOVEL COMPOUNDS
    Publication number: 20100256103
    Abstract: The present invention provides named compounds of formula (I) and pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: March 30, 2010
    Publication date: October 7, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Frank Burkamp, Peter Hansen, Balint Gabos, Håkan Bladh
  • COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS
    Publication number: 20100249112
    Abstract: A combination, comprising a checkpoint kinase (CHK) inhibitor, or a pharmaceutically acceptable salt thereof, and a poly (ADP-ribose)polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt thereof is described.
    Type: Application
    Filed: May 23, 2008
    Publication date: September 30, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Mark James O'Connor, Graeme Cameron Murray Smith, Sonya Zabludoff
  • PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS
    Publication number: 20100210648
    Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Application
    Filed: February 26, 2010
    Publication date: August 19, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Bin Wang, Tao Wang
  • PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES
    Publication number: 20100152219
    Abstract: Compounds of formula (I): and their use in the inhibition of Trk activity are described.
    Type: Application
    Filed: February 25, 2010
    Publication date: June 17, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Michael Howard Block, John W. Lee, David Scott, Haixia Wang, Tao Wang, Dingwei Yu, Yongxin Han, John Anthony Josey, Bin Wang
  • N-(2-AMINIPHENYL)-4-(5-((ETHYLAMINO)METHYL)-1,2-THIAZOL-2-YL) BENZAMIDE AND N-(2-AMINOPHENYL)-4-(5-((ISOPROPYLAMINO)METHYL)-1,2-THIAZOL-2-YL) BENZAMIDE AS HDAC INHIBITORS
    Publication number: 20090312556
    Abstract: The invention concerns novel benzamide compounds of Formula (I): wherein R wherein is ethyl or isopropyl; or a pharmaceutically acceptable salt or pro-drug form thereof. The invention also concerns processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase (HDAC).
    Type: Application
    Filed: December 15, 2005
    Publication date: December 17, 2009
    Applicant: ASTRAZENECA R& D ALDERLY
    Inventors: Elaine Sophie, Elizabeth Stokes, Gregory Carr
  • New Benzimidazole Derivatives
    Publication number: 20080221188
    Abstract: Provided herein are compounds in accord with Formula I: that are useful in the treatment of pain.
    Type: Application
    Filed: August 9, 2007
    Publication date: September 11, 2008
    Applicant: AstraZeneca R&D Sodertalje
    Inventors: William Brown, Shawn Johnstone, Denis Labrecque
  • Chemical compounds
    Publication number: 20070112000
    Abstract: The use of compounds of formula (I) wherein variable groups are defined within; in the manufacture of medicaments for use in the inhibition of 11?HSD1, process for making them, certain compounds within the definition of the formula (I) and pharmaceutical compositions comprising them are described. The compounds are useful in the treatment of metabolic syndrome, diabetes and obesity.
    Type: Application
    Filed: November 4, 2004
    Publication date: May 17, 2007
    Applicant: AstraZeneca R&D Alderley
    Inventors: Peter Barton, Roger Butlin, Janet Pease